

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

O I P TRANSMITTAL FORM		Application Number	10/532,547
AUG 08 2005 U.S. PATENT AND TRADEMARK OFFICE		Filing Date	4/22/2005
		First Named Inventor	Plowman
		Art Unit	
		Examiner Name	
Total Number of Pages in This Submission	295	Attorney Docket Number	EX03-075C-US

ENCLOSURES (check all that apply)			
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC	
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences	
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)	
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information	
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter	
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Receipt Postcard	
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund		
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____		
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Landscape Table on CD		
<input type="checkbox"/> Reply to Missing Parts/- Incomplete Application	Remarks		
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53			

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm	Exelixis, Inc.		
Signature			
Printed Name	Laleh Shayesteh		
Date	August 4, 2005	Reg. No.	47,937

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Signature			
Typed or printed name	Laleh Shayesteh	Date	August 4, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of Plowman *et al.*

Application No.: 10/532,547

Filed: April 22, 2005

For: MBMS AS MODIFIERS OF
BRANCHING MORPHOGENESIS
AND METHODS OF USE

Confirmation No.: 6196

Art Unit: Not Assigned

Examiner: Not Assigned

Attorney Docket No.: EX03-075C-US

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


In accordance with 37 C.F.R §1.56, this Information Disclosure Statement is being submitted for the above-referenced application.

In accordance with 37 C.F.R §1.97 (g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined by 37 C.F.R. §1.56 exists.

In accordance with 37 C.F.R §1.97 (h), the disclosure contained herein is not intended to constitute an admission that any patent, publication, or other information referred to is "prior art" or "analogous art" for this invention.

The Commissioner is hereby authorized to charge any required fees, if necessary, to Deposit No. 50-1108.

Respectfully submitted,


Laleh Shavesteh Reg. No. 47,937
Tel: (650) 837-8223; Fax: (650) 837-8234

Dated: August 4, 2005



AUG 8 2005

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

6

Complete if Known

Application Number	10/532,547
Filing Date	4/22/2005
First Named Inventor	Plowman
Art Unit	
Examiner Name	

Attorney Docket Number EX03-075C-US

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	1	NCBI Annotation Project. Homo sapiens calcium/calmodulin-dependent protein kinase (CaM kinase) II gamma (CAMK2G), mRNA. GI:22051042. 01-AUG-2002
	2	Xie,S., et al. Homo sapiens polo-like kinase 3 (Drosophila) (PLK3), mRNA. GI:4758015 30-JAN-2004
	3	Strausberg,R.L., et al. Homo sapiens phosphatidylinositol-4-phosphate 5-kinase, type II, gamma (PIP5K2C), mRNA. GI:21322229 07-SEP-2003
	4	Sagara,N., et al. Homo sapiens frizzled homolog 7 (Drosophila) (FZD7), mRNA. GI:4503832 22-APR-2005
	5	Li,J., et al. Homo sapiens glycogen synthase kinase 3 beta (GSK3B), mRNA. GI:21361339 26-JUL-2005
	6	Nupponen NN et al. Homo sapiens homeodomain-interacting protein kinase 3 (HIPK3), mRNA. GI:11386208 28-NOV-2000
	7	Price,V.E., et al. Homo sapiens v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT), mRNA. GI:4557694 01-AUG-2005.
	8	Pastore,S., et al. Homo sapiens mitogen-activated protein kinase 1 (MAPK1), transcript variant 1, mRNA. GI:20986528 23-MAY-2005
	9	Llib,S., et al. Homo sapiens mitogen-activated protein kinase 10 (MAPK10), transcript variant 1, mRNA. GI:20986504 22-APR-2005
	10	NCBI Annotation Project. Homo sapiens similar to Milogen-activated protein kinase 6 (Extracellular signal-regulated kinase 3) (ERK-3) (MAP kinase isoform p97) (p97-MAPK) (LOC160848), mRNA. GI:18581345 01-AUG-2002
	11	Rai,R., et al. Homo sapiens mitogen-activated protein kinase 6 (MAPK6), mRNA. GI:16306569 14-MAY-2005

Examiner Signature	/Karen A. Canella, Ph.D./	Date Considered	12/22/2008
--------------------	---------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication from applicant.

Applicant's English citation may be used for examination. Applicant is requested to attach a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KAC/



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

2

of

6

Complete if Known

Application Number 10/532,547

Filing Date 4/22/2005

First Named Inventor Plowman

Art Unit

Examiner Name

Attorney Docket Number EX03-075C-US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	12	Robinson,M.J. et al. Homo sapiens mitogen-activated protein kinase 4 (MAPK4), mRNA. GI:6715608 29-JUN-2005	
	13	Lu,K.P. et al. Homo sapiens NIMA (never in mitosis gene a)-related kinase 4 (NEK4), mRNA. GI:4507276 22-APR-2005	
	14	Liu,Y., et al. Homo sapiens neurotrophic tyrosine kinase, receptor, type 2 (NTRK2), mRNA. GI:21361305 23-AUG-2004	
	15	Razeghi,P., et al. Homo sapiens pyruvate dehydrogenase kinase, isoenzyme 4 (PDHK4), mRNA. GI:4505692 07-APR-2003	
	16	Liu,F., et al. Homo sapiens membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase (PKMYT1), mRNA. GI:21361082 06-APR-2003	
	17	Higuchi,H., et al. Homo sapiens protein kinase, cAMP-dependent, catalytic, beta (PRKACB), transcript variant 2, mRNA. GI:4506056 23-DEC-2003	
	18	Tanimura,A., et al. Homo sapiens protein kinase, cAMP-dependent, catalytic, alpha (PRKACA), mRNA. GI:4506054 07-APR-2003	
	19	Zhang,B., et al. Homo sapiens protein kinase C, alpha (PRKCA), mRNA. GI:4506066 23-DEC-2003	
	20	Shibukawa,Y., Homo sapiens protein kinase C, delta (PRKCD), mRNA. GI:5453969 07-APR-2003	
	21	Rohwer,A., et al. Homo sapiens PTK9L protein tyrosine kinase 9-like (A6-related protein) (PTK9L), mRNA. GI:6005845 07-APR-2003	
	22	Beeler,J.F., et al. Homo sapiens PTK9 protein tyrosine kinase 9 (PTK9), mRNA. GI:4506274 07-APR-2003	

Examiner Signature	/Karen A. Canella, Ph.D./	Date Considered	12/22/2008
--------------------	---------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹

² Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KAC/



AUG 8 2005

PTO/SB/08b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

3

of

6

Complete if Known

Application Number 10/532,547

Filing Date 4/22/2005

First Named Inventor Plowman

Art Unit

Examiner Name

Attorney Docket Number EX03-075C-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	23	Akuta,S.M., et al. Homo sapiens v-raf-1 murine leukemia viral oncogene homolog 1 (RAF1), mRNA. GI:4506400 23-AUG-2004	
	24	Huang,C.Y., et al. Homo sapiens serine/threonine kinase 24 (STE20 homolog, yeast) (STK24), mRNA. GI:20070157 11-JUN-2005	
	25	Osada,S., et al. Homo sapiens serine/threonine kinase 25 (STE20 homolog, yeast) (STK25), mRNA. GI:21361357 06-APR-2003	
	26	NCBI Annotation Project. Homo sapiens serine/threonine kinase 38 like (STK38L), mRNA. GI:22058228 01-AUG-2002	
	27	Tripathi,N., et al. Homo sapiens serine/threonine kinase 38 (STK38), mRNA. GI:6005813 08-APR-2003	
	28	NCBI Annotation Project. Homo sapiens similar to tousled-like kinase 2 (Arabidopsis);protein kinase U-alpha; Tousled-like kinase (Arabidopsis) (LOC20231), mRNA. GI:22052588 01-AUG-2002	
	29	Silije,H.H., et al. Homo sapiens tousled-like kinase 2 (TLK2), mRNA. GI:11140818 03-FEB-2004	
	30	Yoshizawa-Sugata,N., et al. Homo sapiens CDC7 cell division cycle 7 (S. cerevisiae) (CDC7), mRNA. GI:11038647 11-JUN-2005	
	31	Stevanin,G., et al. Homo sapiens protein kinase, cAMP-dependent, catalytic, gamma (PRKACG), mRNA. GI:15619014 23-APR-2005	
	32	Nghiem,P., et al. Ca2+/calmodulin-dependent protein kinase (EC 2.7.1.123) II gamma chain, splice form B - human. GI:422769 01-DEC-2000	
	33	Xie,S., et al. polo-like kinase 3; cytosine-inducible kinase; proliferation-related kinase; FGF-inducible kinase [Homo sapiens]. GI:4758016 30-JAN-2004	

Examiner Signature	/Karen A. Canella, Ph.D./	Date Considered	12/22/2008
--------------------	---------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KAC/



PTO/SB/08b (08-03)

Approved for use through 07/1/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Information Disclosure Statement by Applicant

(Use as many sheets as necessary)

Sheet 4 of 6

Complete if Known

Application Number	10/532,547
Filing Date	4/22/2005
First Named Inventor	Plowman
Art Unit	
Examiner Name	

Attorney Docket Number EX03-075C-US

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	34	Strausberg,R.L., et al. Phosphatidylinositol-4-phosphate 5-kinase, type II, gamma [Homo sapiens]. GI:20306910 28-JUL-2005.
	35	Sagara,N., et al. frizzled 7 [Homo sapiens]. GI:4503833 22-APR-2005
	36	Lau KF, et al. glycogen synthase kinase 3 beta [Homo sapiens]. GI:4504163 31-OCT-2000
	37	Nupponen NN et al. homeodomain-interacting protein kinase 3 [Homo sapiens]. GI:11386208 28-NOV-2000
	38	Price,V.E., et al. v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog precursor [Homo sapiens]. GI:4557695 01-AUG-2005
	39	Li,L., et al. mitogen-activated protein kinase 1; protein kinase, mitogen-activated 1 (MAP kinase 1; p40, p41); p41mapk [Homo sapiens]. GI:4506087 31-OCT-2000
	40	Li,B.S., et al. mitogen-activated protein kinase 10 isoform 1 [Homo sapiens]. GI:4506081 22-APR-2005
	41	NCBI Annotation Project. similar to Mitogen-activated protein kinase 6 (Extracellular signal-regulated kinase 3) (ERK-3) (MAP kinase isoform p97) (p97-MAPK) [Homo sapiens]. GI:18581346 01-AUG-2002
	42	Rei,R., et al. mitogen-activated protein kinase 6 [Homo sapiens]. GI:4506091 14-MAY-2005
	43	Robinson,M.J. et al. mitogen-activated protein kinase 4 [Homo sapiens]. GI:4506089 29-JUN-2005
	44	Lu,K.P. et al. NIMA (never in mitosis gene a)-related kinase 4 [Homo sapiens]. GI:4507277 22-APR-2005

Examiner Signature	/Karen A. Canella, Ph.D./	Date Considered	12/22/2008
--------------------	---------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/06b (09-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1615 PTO/USPTO FORMS

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

5

of

6

Complete if Known

Application Number	10/532,547
Filing Date	4/22/2005
First Named Inventor	Plowman
Art Unit	
Examiner Name	

Attorney Docket Number EX03-075C-US

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	45	Valent,A., et al. neurotrophic tyrosine kinase, receptor, type 2 [Homo sapiens]. GI:5453812 01-NOV-2000
	46	Savkur,R.S., et al. pyruvate dehydrogenase kinase, isoenzyme 4 [Homo sapiens]. GI:4505693 23-APR-2005
	47	Liu,F., et al. membrane-associated tyrosine- and threonine-specific cdc2-inhibi [Homo sapiens]. GI:4758928 14-MAY-2002
	48	Hanamoto,T., et al. cAMP-dependent protein kinase catalytic subunit beta isoform 2 [Homo sapiens]. GI:4506057 29-JUN-2005
	49	Martin,M.C., et al. cAMP-dependent protein kinase catalytic subunit alpha isoform 1 [Homo sapiens]. GI:4506055 14-JUN-2005
	50	Smith,J.M., et al. protein kinase C, alpha [Homo sapiens]. GI:4506067 27-JUL-2005
	51	Shibukawa,Y., et al. protein kinase C, delta [Homo sapiens]. GI:5453970 07-APR-2003
	52	Rohwer,A., et al. twinfilin-like protein [Homo sapiens]. GI:6005846 14-MAY-2005
	53	Ojala,P.J., et al. PTK9 protein tyrosine kinase 9; protein tyrosine kinase 9 [Homo sapiens]. GI:4506275 05-OCT-2003
	54	Mukherjee,R., et al. v-raf-1 murine leukemia viral oncogene homolog 1 [Homo sapiens]. GI:4506401 26-JUL-2005
	55	Zhou,T.H., et al. serine/threonine kinase 24 (STE20 homolog, yeast); serine/threonine kinase 24 (Ste20, yeast homolog); STE20-like kinase 3 [Homo sapiens]. GI:4505261 19-DEC-2001

Examiner Signature	/Karen A. Canella, Ph.D./	Date Considered	12/22/2008
--------------------	---------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KAC/



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for PTO/SB/08A

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

6

of

6

Complete if Known

Application Number	10/532,547
Filing Date	4/22/2005
First Named Inventor	Plowman
Art Unit	
Examiner Name	

Attorney Docket Number EX03-075C-US

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials *	Cite No. ^	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. T ^
	56	Osada,S., et al. serine/threonine kinase 25 (Ste20, yeast homolog); sterile 20 (oxidant stress response kinase 1; yeast Sps1/St20-related kinase1) [Homo sapiens]. GI:5454174 19-DEC-2001
	57	Nagase,T., et al. KIAA0965 protein [Homo sapiens]. GI:4589574 16-JUN-1999
	58	Devroe,E., et al. serine/threonine kinase 38 [Homo sapiens]. GI:6005814 23-APR-2005
	59	NCBI Annotation Project. similar to tousled-like kinase 2 (Arabidopsis); protein kinase U-alpha; Tousled-like kinase (Arabidopsis) [Homo sapiens]. GI:22052589 01-AUG-2002
	60	Sillje,H.H., et al. tousled-like kinase 2; serine/threonine kinase; tousled-like kinase [Homo sapiens]. GI:11140819 03-FEB-2004
	61	Yoshizawa-Sugata,N., et al. CDC7 cell division cycle 7 [Homo sapiens]. GI:4502715 11-JUN-2005
	62	Stevanin,G., et al. protein kinase, cAMP-dependent, catalytic, gamma [Homo sapiens]. GI:15619015 23-APR-2005

Examiner Signature	/Karen A. Canella, Ph.D./	Date Considered	12/22/2008
--------------------	---------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

The collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KAC/